Humacyte (HUMA) Net Income (2020 - 2026)
Humacyte (HUMA) posted quarterly Net Income of -$30.8 million for Q1 2026, down 20.77% year-over-year from -$38.9 million in Q1 2025, and little changed quarter-over-quarter from -$30.9 million in Q4 2025.
Humacyte (HUMA) Net Income (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Net Income for 7 consecutive years, with -$30.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income fell 20.77% year-over-year to -$30.8 million; the TTM figure through Mar 2026 stood at -$179.2 million (down 52.74% YoY), while the FY2025 annual figure was -$116.8 million, up 60.16% from the prior year.
- Net Income was little changed at -$30.8 million in Q1 2026 per HUMA's latest filing, from -$30.9 million in the prior quarter.
- Across five years, Net Income topped out at -$19.7 million in Q2 2022 and bottomed at -$86.0 million in Q3 2025.
- Historically, Net Income has averaged -$30.8 million across 5 years, with a median of -$29.3 million in 2024.
- Annual changes were most pronounced in 2023 — Net Income climbed 23.74% — and 2025, when it tumbled 170.83%.
- Humacyte's Net Income stood at -$21.0 million in 2022, then sank by 42.58% to -$30.0 million in 2023, then gained by 2.14% to -$29.3 million in 2024, then slipped by 5.4% to -$30.9 million in 2025, then climbed by 0.26% to -$30.8 million in 2026.
- Business Quant data shows HUMA's Net Income at -$30.8 million in Q1 2026, -$30.9 million in Q4 2025, and -$86.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | -28.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.93 Mn |
| Mar 31, 2026 | -30.84 Mn |
| Dec 31, 2025 | -30.92 Mn |
| Sep 30, 2025 | -86.02 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -25.54 Mn |
| Dec 31, 2024 | -29.34 Mn |
| Sep 30, 2024 | -31.76 Mn |
| Jun 30, 2024 | -30.70 Mn |
| Mar 31, 2024 | -27.39 Mn |
| Dec 31, 2023 | -29.98 Mn |
| Sep 30, 2023 | -24.72 Mn |
| Jun 30, 2023 | -26.96 Mn |
| Mar 31, 2023 | -22.72 Mn |
| Dec 31, 2022 | -21.03 Mn |
| Sep 30, 2022 | -24.25 Mn |
| Jun 30, 2022 | -19.72 Mn |
| Mar 31, 2022 | -29.80 Mn |
| Dec 31, 2021 | -23.01 Mn |
| Sep 30, 2021 | -31.56 Mn |